Two-Drug sequence aims to clear CLL cells and let patients stop treatment

NCT ID NCT07682415

Not yet recruiting Disease control Sponsor: Yi Shuhua Source: ClinicalTrials.gov ↗

First seen Jul 02, 2026 · Last updated Jul 02, 2026

Summary

This phase 2 trial tests a treatment plan for people with newly diagnosed chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). Participants first take zanubrutinib alone for 12 cycles, then add sonrotoclax for another 12 cycles. The goal is to see if this sequence can make the cancer undetectable in the blood and allow low-risk patients to stop all treatment. The study also monitors side effects and immune function.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: zanubrutinib and sonrotoclax
What this could lead to: If successful, this treatment sequence could offer a time-limited therapy that clears CLL/SLL cells deeply, potentially allowing patients to stop treatment and stay in remission.
What could go wrong: This is an early-phase trial with only 60 participants, so results may not apply to all patients. The combination may cause side effects, and the high-risk group still needs ongoing maintenance therapy.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CLL / SLL are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

B-cell chronic lymphocytic leukemia chronic lymphocytic leukemia/small lymphocytic lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CLL / SLL

Contacts and locations

Locations

Blood Disease Hospital of Chinese Academy of Medical Sciences (Institute of Hematology, CAMS)

Tianjin, Tianjin Municipality, 300000, China
Henan Cancer Hospital

Zhengzhou, Henan, China
Jiangsu Province Hospital

Nanjing, Jiangsu, China
Qilu Hospital of Shandong University

Jinan, Shandong, China
Shenzhen Second People's Hospital

Shenzhen, Guangdong, China
The First Affiliated Hospital of Nanchang University

Nanchang, Jiangxi, China
The Second Xiangya Hospital of Central South University

Changsha, Hunan, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.